Ixazomib as Postinduction Maintenance for Patients With Newly Diagnosed Multiple Myeloma Not Undergoing Autologous Stem Cell Transplantation: The Phase III TOURMALINE-MM4 Trial

Maintenance therapy prolongs progression-free survival (PFS) in patients with newly diagnosed multiple myeloma (NDMM) not undergoing autologous stem cell transplantation (ASCT) but has generally been limited to immunomodulatory agents. Other options that complement the induction regimen with favorab...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:J Clin Oncol
Huvudupphovsmän: Dimopoulos, Meletios A., Špička, Ivan, Quach, Hang, Oriol, Albert, Hájek, Roman, Garg, Mamta, Beksac, Meral, Bringhen, Sara, Katodritou, Eirini, Chng, Wee-Joo, Leleu, Xavier, Iida, Shinsuke, Mateos, María-Victoria, Morgan, Gareth, Vorog, Alexander, Labotka, Richard, Wang, Bingxia, Palumbo, Antonio, Lonial, Sagar
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society of Clinical Oncology 2020
Ämnen:
ORIGINAL REPORTS
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7768338/
https://ncbi.nlm.nih.gov/pubmed/33021870
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.02060
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk